Company profile: Apogenix
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical protein therapeutics for cancer and inflammatory diseases, including Asunercept, a fully human fusion protein for solid tumors, malignant hematological diseases, and COVID-19, and the HERA-ligand technology platform creating receptor agonists targeting TNFSF-dependent pathways; engages in partnerships with pharma, biotech, and academic institutions.
Products and services
- HERA-ligand technology platform: A proprietary receptor-agonist development system creating novel ligands that target TNFSF-dependent signaling pathways with potential broad oncology applications
- Asunercept: A clinical-stage, fully human fusion protein that modulates programmed cell death to treat solid tumors, malignant hematological diseases, and COVID-19, demonstrating significant improvements in clinical trials
- Partnerships and collaborations: A multi-institutional initiative engaging pharmaceutical and biotechnology companies and academic institutions to advance the development and commercialization of Apogenix drug candidates
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Apogenix
Dren Bio
HQ: United States
Website
- Description: Provider of protein engineering technologies for depleting cells, protein aggregates, and other disease-causing agents. Develops antibody therapeutics including DR-01, a fully human, nonfucosylated ADCC-inducing antibody for hematologic malignancies and autoimmune disorders, and a Targeted Myeloid Engager and Phagocytosis Platform with DR-0201 for B cell malignancies and DR-0202 for solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dren Bio company profile →
C4X Discovery
HQ: United Kingdom
Website
- Description: Provider of NMR-based 3D molecular structure determination to optimize drug design and development, partnering with pharma to generate better, safer products. Offers Conformetrix 4D structural design technology, 4Sight visualizer, PatientSeek for genetic patient stratification, and programs including oral α4β7 integrin inhibitors, IL-17A inhibitors (licensed to Sanofi), and NRF2 activators (licensed to AstraZeneca).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C4X Discovery company profile →
Pionyr
HQ: United States
Website
- Description: Provider of immuno-oncology therapeutics that enhance antitumor immunity by targeting the tumor microenvironment. Utilizes novel target discovery and antibody generation platforms and its Myeloid Tuning approach. Programs include PY314 (TREM2) to deplete tumor-associated macrophages, PY159 (TREM1) to repolarize them to counteract immunosuppression, and PY265 (MARCO) to activate immune responses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pionyr company profile →
Cirrus Bio
HQ: United States
Website
- Description: Provider of solutions for common health issues that impact well-being.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cirrus Bio company profile →
PT Theragnostic
HQ: The Netherlands
Website
- Description: Provider of genomics-based personalized analysis for radiation sensitivity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PT Theragnostic company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Apogenix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Apogenix
2.2 - Growth funds investing in similar companies to Apogenix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Apogenix
4.2 - Public trading comparable groups for Apogenix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →